

Boehringer
Ingelheim

Revision	5	Template #	306
Operator	hal	Dimensions	3" x 8-1/2"
Date	21Jun13	Corner Radius25"
Art #	164004-00	PDF	21Jun13 hal
Item #	464003	Rev Level	00
Product	Rhinomune		
Type/Size	Card / 25 x 1 dose		

BLACK

PMS 109

PMS 550

25 x 1 Dose

Rhinomune®

Serial No.:
Exp. Date:

Indications: For vaccination of healthy horses 3 months of age or older as an aid in the prevention of respiratory disease caused by equine herpesvirus type 1 (EHV-1).

Directions and Dosage: Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Shake well. Administer 1 mL intramuscularly.

Primary Vaccination: Healthy horses 3 months of age or older should receive 2 doses administered 3-4 weeks apart. Foals should be vaccinated when maternal antibodies have declined, generally at 3 months of age. If vaccinated earlier, foals should receive the 2-dose series after reaching 3 months of age. Pregnant mares should be vaccinated after the second month of pregnancy.

Revaccination: Revaccination every 3 months with a single dose is recommended.

See reverse side for complete information.

Equine Rhinopneumonitis Vaccine

Modified Live Virus

Rhinomune®

25 x 1 Dose

This package contains 25 x 1 dose vials of lyophilized vaccine and 25 x 1 mL vials of sterile diluent.

Storage: Store at 35-45°F (2-7°C). Protect from light. Do not freeze.

Preservative: Gentamicin.

Boehringer Ingelheim Vetmedica, Inc.
St. Joseph, MO 64506
US Vet. Lic. No. 124
Code 164-031



Boehringer
Ingelheim

Rhinomune®

25 x 1 Dose



164004-00

BLACK

Precautions: Sterilized syringes and needles should be used for administration. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Do not vaccinate within 21 days before slaughter. Burn containers and all unused contents. Anaphylactoid reactions may occur following use. Antidote: Epinephrine.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Disease Description: Primary infection with EHV-1 causes an acute respiratory disease characterized by nasal discharge, coughing, labored breathing, fever, slight loss of appetite, and depression. Annual outbreaks may occur among foals in areas with a large equine population.

Clinical signs, occasionally persisting as long as 7 days, are generally more severe in young horses, and may be exacerbated by strenuous activity. Subclinical reinfection may also occur, with latent carriers the probable reservoir of EHV-1. Immunity following natural infection typically endures for 3-9 months and is usually enhanced by subclinical or mild reinfection.

Reference:

Witherspoon DM: Vaccination against equine herpesvirus 1 and equine influenza infection. *Vet Rec* 115:363, 1984.

Rhinomune® is a registered trademark of Boehringer Ingelheim Vetmedica, Inc.

© 2013 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.